263 related articles for article (PubMed ID: 36672509)
21. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
22. Organoid of ovarian cancer: genomic analysis and drug screening.
Liu HD; Xia BR; Jin MZ; Lou G
Clin Transl Oncol; 2020 Aug; 22(8):1240-1251. PubMed ID: 31939100
[TBL] [Abstract][Full Text] [Related]
23. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
24. 3D dynamic cultures of HGSOC organoids to model innovative and standard therapies.
Cavarzerani E; Caligiuri I; Bartoletti M; Canzonieri V; Rizzolio F
Front Bioeng Biotechnol; 2023; 11():1135374. PubMed ID: 37143603
[TBL] [Abstract][Full Text] [Related]
25. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment.
Hoffmann K; Berger H; Kulbe H; Thillainadarasan S; Mollenkopf HJ; Zemojtel T; Taube E; Darb-Esfahani S; Mangler M; Sehouli J; Chekerov R; Braicu EI; Meyer TF; Kessler M
EMBO J; 2020 Mar; 39(6):e104013. PubMed ID: 32009247
[TBL] [Abstract][Full Text] [Related]
26. Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells.
Ho BX; Pek NMQ; Soh BS
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561796
[TBL] [Abstract][Full Text] [Related]
27. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
28. Organoid technology and applications in cancer research.
Xu H; Lyu X; Yi M; Zhao W; Song Y; Wu K
J Hematol Oncol; 2018 Sep; 11(1):116. PubMed ID: 30219074
[TBL] [Abstract][Full Text] [Related]
29. Modeling and Targeting Alzheimer's Disease With Organoids.
Papaspyropoulos A; Tsolaki M; Foroglou N; Pantazaki AA
Front Pharmacol; 2020; 11():396. PubMed ID: 32300301
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.
Servant R; Garioni M; Vlajnic T; Blind M; Pueschel H; Müller DC; Zellweger T; Templeton AJ; Garofoli A; Maletti S; Piscuoglio S; Rubin MA; Seifert H; Rentsch CA; Bubendorf L; Le Magnen C
J Pathol; 2021 Aug; 254(5):543-555. PubMed ID: 33934365
[TBL] [Abstract][Full Text] [Related]
31. Prostate organoid technology - the new POT of gold in prostate stem cell and cancer research.
Mai CW; Shu Y; Cheong SK; Chua CW
Sheng Li Xue Bao; 2021 Apr; 73(2):181-196. PubMed ID: 33903880
[TBL] [Abstract][Full Text] [Related]
32. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
33. Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review).
Sisman Y; Schnack T; Høgdall E; Høgdall C
Mol Clin Oncol; 2022 Feb; 16(2):29. PubMed ID: 34987799
[TBL] [Abstract][Full Text] [Related]
34. Is there a relationship in-between ovarian endometriosis and ovarian cancer? Immunohistochemical profile of four cases with coexisting ovarian endometriosis and cancer.
Penciu RC; Postolache I; Steriu L; Izvoranu S; Tica AA; Mocanu ID; Sârbu V; Deacu M; Tica I; Bălţătescu GI; Tica OS; Tica VI
Rom J Morphol Embryol; 2020; 61(1):157-165. PubMed ID: 32747907
[TBL] [Abstract][Full Text] [Related]
35. Advances in Central Nervous System Organoids: A Focus on Organoid-Based Models for Motor Neuron Disease.
Vieira de Sá R; Cañizares Luna M; Pasterkamp RJ
Tissue Eng Part C Methods; 2021 Mar; 27(3):213-224. PubMed ID: 33446055
[TBL] [Abstract][Full Text] [Related]
36. Next-Generation Liver Medicine Using Organoid Models.
Akbari S; Arslan N; Senturk S; Erdal E
Front Cell Dev Biol; 2019; 7():345. PubMed ID: 31921856
[TBL] [Abstract][Full Text] [Related]
37. Emerging and Evolving Ovarian Cancer Animal Models.
Bobbs AS; Cole JM; Cowden Dahl KD
Cancer Growth Metastasis; 2015; 8(Suppl 1):29-36. PubMed ID: 26380555
[TBL] [Abstract][Full Text] [Related]
38. Patient-derived organoid (PDO) platforms to facilitate clinical decision making.
Liu L; Yu L; Li Z; Li W; Huang W
J Transl Med; 2021 Jan; 19(1):40. PubMed ID: 33478472
[TBL] [Abstract][Full Text] [Related]
39. Advances in liver organoids: model systems for liver disease.
Lee J; Mun SJ; Shin Y; Lee S; Son MJ
Arch Pharm Res; 2022 Jun; 45(6):390-400. PubMed ID: 35661984
[TBL] [Abstract][Full Text] [Related]
40. Three-Dimensional Organoids in Cancer Research: The Search for the Holy Grail of Preclinical Cancer Modeling.
Dzobo K; Rowe A; Senthebane DA; AlMazyadi MAM; Patten V; Parker MI
OMICS; 2018 Dec; 22(12):733-748. PubMed ID: 30571609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
